Leaders in healthcare. Innovators in life.

Dr [First Name] [Last Name]
Hospital/Surgery
Address1
Address2
Address 3

April 4th 2011

IMPORTANT SAFETY INFORMATION ON EFIENT (prasugrel) AND REPORTS OF HYPERSENSITIVITY INCLUDING ANGIOEDEMA

Dear Dr [Last Name],

In agreement with the European Medicines Agency and the Irish Medicines Board (IMB), Daiichi Sankyo and Eli Lilly and Company would like to inform you of important safety information:

Summary

Case reports have been received which describe serious hypersensitivity reactions including angioedema in patients receiving prasugrel. Some of these reports concern patients with a history of hypersensitivity reactions to clopidogrel.

As a result, the Efient Product Information has been updated to reflect this new information. Please be aware of the following recommendations:

- When prescribing Efient, it is important for prescribers to inform patients of the potential risk of hypersensitivity reactions.
- Prescribers should particularly be aware of the potential risk of hypersensitivity reactions, including angioedema in patients with a previous known history of hypersensitivity reactions to thienopyridines.
- Patients should be advised to tell the physician immediately if they experience symptoms suggestive of hypersensitivity.

The product information (SmPC and package leaflet) will be revised to include the new safety information (see Annex for CHMP recommended revision's of the SmPC wording).

Further information on the safety concern

Cases reported had a variable time to onset, ranging from immediate over a few hours to 5-10 days. Some patients with no prior exposure to clopidogrel experienced hypersensitivity reactions however other patients with a history of hypersensitivity to clopidogrel had been switched to prasugrel and subsequently experienced angioedema.

Daiichi Sankyo Ireland Limited
Building 1 ● Swift Square ● Northwood Avenue ● Santry ● Dublin 9 ● Phone: (01) 489-3000 ● Fax: (01) 4893033
Eli Lilly and Company (Ireland) Limited ● Hyde House ● 65 Adelaide Road ● Dublin 2 ● Phone: 00353 (0)1-6614377 ● Fax: (01) 6614476

Call for Reporting

Healthcare professionals are reminded of the need to report any adverse reactions suspected to be associated with the use of Efient to:

Irish Medicines Board,
Kevin O'Malley House,
Earlsfort Centre,
Earlsfort Terrace,
Dublin 2,
Ireland.
Tel: 01-676 4971
Fax: 01-676 7836

or by using the on-line adverse reaction form on the IMB website at www.imb.ie

Contact details for reporting to Marketing Authorisation Holder are:

GPS UK Affiliate
Eli Lilly & Co Ltd
Erl Wood Manor
Sunninghill Road
Windlesham, Surrey
GU20 6PH, UK
E-mail: UK_TEAM_GBMAIL-GPS@LILLY.COM
Fax: +44 (0)1276 452463
Tel: +44 (0) 1256 315000

Communication information

Should you have any questions or concerns regarding this important safety information, please contact the Lilly Medical Department at Lilly Ireland, Hyde House, 65 Adelaide Road, Dublin 2, Telephone 01 6614377 or call the Daiichi Sankyo/Lilly Clinical Service Centre via 01 5245108.

Yours sincerely,



Dr Anne Tobin
Medical Manager
Lilly Ireland

Mary Maguire
Medical Science Manager
Daiichi Sankyo Ireland

Annex:

SmPC

4.4 Special warnings and precautions for use

Hypersensitivity including angioedema

Hypersensitivity reactions including angioedema has been reported in patients receiving prasugrel including in patients with a history of hypersensitivity reaction to clopidogrel. Monitoring for signs of hypersensitivity in patients with a known allergy to thienopyridines is advised (see section 4.8.)

4.8 Undesirable effects

b. Tabulated summary of adverse reactions

Table 2 summarises haemorrhagic and non-haemorrhagic adverse reactions in TRITON, or that were spontaneously reported, classified by frequency and system organ class. Frequencies are defined as follows:

Very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1000 to < 1/100);
rare (≥ 1/10,000 to <1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data).

Table 2: **Haemorrhagic and Non-haemorrhagic adverse reactions**

System Organ Class	**Common**	**Uncommon**	**Rare**	**Not Known**
Blood and Lymphatic System disorders	Anaemia		Thrombocytopaenia	Thrombotic thrombocytopaenic purpura (TTP) *-see section 4.4*
Immune system disorders		**Hypersensitivity including angioedema**		
Eye disorders		Eye haemorrhage		
Vascular Disorders	Haematoma			
Respiratory, thoracic and mediastinal disorders	Epistaxis	Haemoptysis		
Gastrointestinal disorders	Gastrointestinal haemorrhage	Retroperitoneal haemorrhage Rectal haemorrhage Haematochezia Gingival bleeding		
Skin and subcutaneous tissue disorders	Rash Ecchymosis			
Renal and urinary disorders	Haematuria			
General disorders and administration site conditions	Vessel puncture site haematoma Puncture site haemorrhage			
Injury, poisoning and procedural complications	Contusion	Post-procedural haemorrhage	Subcutaneous haematoma	